Ossification of ligamentum flavum (OLF) is a pathological ectopic ossification in the spinal ligament, leading to spinal canal stenosis, but little was known about its pathogenesis. A previous study has found growth/differentiation factor (GDF)-5 expression at ossified sites of the ligaments from OLF patients. This study aimed to investigate the osteogenic effects of GDF-5 on cultured human ligamentum flavum cells (LFCs). LFCs were isolated from human spinal ligamentum flavum, and treated with or without recombinant human (rh) GDF-5. Alkaline phosphatase (ALP) activity was measured. Expression of osteocalcin was assessed by reverse transcriptase-PCR, Western blotting and immunofluorescence. Matrix mineralization was assessed by alizarin red staining. Activation of mitogen-activated protein kinases (MAPK) ERK1/2, p38 and JNK were detected by Western blotting. We found that rhGDF-5 treatment increased ALP activity and osteocalcin expression in a time-and dosedependent manner, and induced mineralized nodule form. In addition, rhGDF-5 challenge mediated the ERK1/2 and p38 activation but not JNK. Inhibiting this activation pharmacologically, using U0126, a ERK1/ 2 inhibitor, or SB203580, a p38 inhibitor, resulted in significantly lower ALP activity and osteocalcin protein expression. The present study shows that rhGDF-5 induces osteogenic differentiation of human LFCs through activation of ERK1/2 and p38 MAPK. These findings give some new insight into the pathogenesis of OLF.
Introduction
Ossification of ligamentum flavum (OLF) is characterized by an ectopic bone formation in the spinal ligamentum flavum which is normally composed of elastic and collagen fibers [1] . OLF is a well-recognized cause of spinal canal stenosis resulting in myeloradiculopathy, particularly in Asian population [2] . Previous studies have suggested that some factors, such as genetic background [3] , diabetes mellitus [4] , fluorosis [5] , ankylosing spondylitis [6] , mechanical stress [7] and regional cytokines or growth factors [8, 9] , were involved in the onset and progression of OLF, but the underlying pathogenesis of this disease is still largely unknown.
Growth/differentiation factor (GDF)-5 also called as bone morphogenetic protein (BMP)-14 and cartilagederived morphogenetic protein (CDMP)-1 is a number of the transforming growth factor beta superfamily [10, 11] . The osteogenic potential of recombinant human (rh) GDF5 has been intensively examined in vitro and in vivo for a decade. The in vitro response to rhGDF-5 resulted in osteogenic differentiation in various cell types, such as pluripotent mesenchymal precursor cell C2C12 [12] , adipose-derived stromal cells [13] , bone marrow mesenchymal stem cells [14] and periosteum-derived cells [15] . Matrices loaded with rhGDF-5 induced ectopic bone formation when implanted in rat subcutaneous or intramuscular sites [16, 17] . Application of rhGDF-5 combined with collagen matrix enhanced spinal fusion in rabbit or sheep models [18, 19] . Recently, GDF-5 expression has been only detected in ossified spinal ligaments from OLF patients, which indicated GDF-5 as an important contributor to the pathogenesis of OLF [20] . However, the molecular mechanism of the osteogenic effects of GDF-5 on OLF has not been explored.
Mitogen-activated protein kinases (MAPK), a family of serine/threonine kinases, play an important role in signal transduction and regulation of gene transcription in response to changes of the cellular environment [21] . Three major subfamilies of MAPK, extracellular signalregulated kinase (ERK), p38 kinase (p38) and c-Jun Nterminal kinase (JNK) were associated with human pathological conditions [22] . Moreover, MAPK regulated key cellular functions such as proliferation, differentiation, migration and apoptosis [21] . Previous study found that the MAPK signaling cascade was activated along with the expression of various osteomarkers during the differentiation of osteogenic cells, which indicated that MAPK play an important role in cell osteogenic differentiation [23] .
We hypothesized that GDF-5 can induce osteogenic differentiation of human ligamentum flavum cells (LFCs). This study aimed to test this hypothesis by investigating: (1) the osteogenic effects of rhGDF-5 on cultured LFCs by detecting the change of alkaline phosphatase (ALP) activity, osteocalcin expression and mineralized nodule formation, (2) the activation of MAPK signalings, and (3) involvement of activated MAPK in rhGDF-5-induced osteogenic differentiation of LFCs.
Materials and Methods

Ligamentum Flavum Specimens
The ligamentum flavum specimens were harvested from eight patients who underwent surgical decompression for the fracture of thoracic spine or thoracolumbar junction spine. Surrounding tissues were carefully removed under a dissecting microscope. To avoid any possible contamination by osteogenic cells, the ligaments were carefully extirpated at a distance from ligament-bone insertions. Any ossification case was excluded with images of x-ray, computed tomography and magnetic resonance imaging. Informed consent was obtained from each patient, and the project was approved by the Ethics Committee of Southern Medical University.
LFCs Cultures and Treatment
LFCs cultures were performed as previously described [24] . Briefly, The collected ligaments were washed with phosphate-buffered saline (PBS) several times, minced into about 0.5 mm 2 pieces, and then digested at 37 °C for 60 min by 0.2% collagenase type I (Sigma-Aldrich. St. Louis, MO, USA). Collagenase-treated ligament pieces were washed with DMEM (Gibco BRL, Melbourne, Victoria, Australia) and then placed in 6-well plates (Corning-Costar, Oneonta, NY, USA) in DMEM supplemented with 10% fetal bovine serum (Gibco BRL.), 100 U/ml penicillin and 100 pg/ml streptomycin, and incubated in 95% air/5% CO 2 atmosphere at 37 °C, LFCs were harvested with 0.2% trypsin (Sigma-Aldrich)/0.02% ethylenediamine tetraacetic acid once they migrated from the explants and became confluent. The third passage LFCs were used in the following studies [25] .
In the differentiation experiments, LFCs were treated with different concentrations of rhGDF-5 (ProSpec-Tany TechnoGene, Rehovot, Israel) ranging from 0 to 500 ng/ml for 10 days, or with 100 ng/ml rhGDF-5 for 0 to 14 days, and then subjected to analysis of alkaline phosphatase (ALP) activity, mRNA and protein expression of osteocalcin. In addition, LFCs were treated with or without 100 ng/ml rhGDF-5 for 4 weeks to detect matrix mineralization. In order to detect MAPK activation, LFCs were exposed to 100 ng/ml rhGDF-5 at 0, 5, 15, 30, 60, 120 and 240 minutes. Inhibition experiments were subsequently carried out by pretreatment for 60 minutes with or without different MAPK inhibitors.
Alkaline phosphatase (ALP) activity assay
After LFCs were collected, cell extract was prepared with RIPA lysis buffer (Beyotime Bio, Haimen, China). ALP activity in the cell lysates was assayed at the end of the incubation with ALP substrate buffer (Jiancheng Bio, Nanjing, China) containing the soluble substrate p-nitrophenyl phosphate according to the manufacturer's instruction. The enzyme activity was normalized against cellular protein concentration and was expressed as U/g protein. Protein concentration was determined using the Bradford method [26] .
Reverse transcriptase (RT)-PCR
For semiquantitative measurement of osteocalcin mRNA expression, total RNA was extracted from LFCs using the TRI Reagent ® (Molecular Research Center, Cincinnati, OH, USA). 0.5 µg of each RNA sample was converted to cDNA using PrimeScript TM RT reagent kit (Takara, Dalian, China). Equal amount of cDNA was subsequently amplified by PCR using GoTaq® Green Master Mix (Promega, Madison, WI, USA). Specific oligonucleotide primers were designed on the basis of human sequences in GenBank as following: osteocalcin: Sense 5'-ATG AGA GCC CTC ACA CTC CTC-3', and antisense 5'-GCC GTA GAA GCG CCG ATA GGC-3'; β-actin: sense 5'-GAC TAC CTC ATG AAG ATC CT-3', and antisense 5'-CCA CAT CTG CTG GAA GGT GG-3'. PCR conditions consisted of 35 cycles of denaturing at 94 °C for 30s, annealing at 60 °C for osteocalcin, 55°C for β-actin for 30s, and extension at 72 C for 30s. PCR products (osteocalcin: 294 bp; β-actin: 510 bp) were electrophoresed on 1.5% agarose gel, stained with ethidium bromide. Bands were visualized and analyzed using Eel Documentation and Analysis System (Uvitec, Cambridge, UK). Relative expression of osteocalcin was estimated by using β-actin mRNA as an internal control.
Western blotting
Western blotting was carried out as described previously [27] . Briefly, LFCs were washed with cold PBS and lysed with RIPA lysis buffer. Cell lysates were separated by tricine-SDS-PAGE for osteocalcin analysis or 10% SDS-PAGE for other protein analyses and electrotransferred subsequently onto polyvinylidene difluoride membranes. The membrane blots were probed with a primary antibody overnight at 4 °C, and incubated with appropriate horseradish peroxidase conjugated secondary antibody for 1 hour at room temperature, and visualized by enhanced chemiluminescent kit (Pierce, Rockford, IL, USA). The primary antibodies were goat anti-osteocalcin, rabbit anti-β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-ERK1/2, rabbit anti-phosphor-ERK1/2, rabbit anti-p38, rabbit anti-phosphor-p38, rabbit anti-JNK, rabbit antiphosphor-JNK (Cell Signaling Technology, Danvers, MA, USA).
Immunofluorescence
LFCs were analyzed for osteocalcin expression by immunofluorescence staining as described previously [24] . Briefly, the cell monolayers on glass coverslips were fixed with 4% paraformaldehyde and permeabilized with 0.5% TritonX-100. After washing and blocking, the cells were incubated with a goat anti-osteocalcin antibody (1:25, Santa Cruz Biotechnology) overnight at 4 °C. After washing, the cells were incubated for 60 minutes with fluorescein isothiocyanate (FITC)-conjugated rabbit anti-goat IgG (1:100, ZSGB-BIO Inc, Beijing, China) at 37 °C. The nuclear was subsequently stained for 10 minutes with propidium iodide (PI) (Sigma-Aldrich.) at 37 °C. Immunostained cells were observed under LSM-510 confocal scanning microscopy (Carl Zeiss, Göttingen, Germany).
Alizarin red staining
We adopted the Alizarin-red staining method [28] to determine mineralization of extracellular matrix. Cells were washed with PBS, and fixed with ice-cold 70% ethanol for 60 minutes. After washed, cells were stained with 40 mM Alizarin red (Sigma-Aldrich.), pH 4.2, for 30 minutes at room temperature. Following the staining, cells were rinsed five times with distilled water and incubated in PBS for 15 min with gentle agitation to remove nonspecific Alizarin-red stain. Stained cultures were photographed using microscopy (IX71, Olympus, Tokyo, Japan).
Statistical Analysis
All experiments were repeated at least three times. Data are presented as mean ± standard error (SE). Differences between groups were assessed using Repeated Measures ANOVA. The statistical software package SPSS 13.0 was used for statistical analyses in this study. Two-tailed P < 0.05 was considered statistically significant.
Results
rhGDF-5 induced osteogenic differentiation of LFCs
ALP activity, osteocalcin expression and matrix mineralization are the main markers of osteogenesis [29] . We examined these markers in LFCs treated with or without rhGDF-5. As shown in Fig. 1 , rhGDF-5 treatment increased significantly ALP activity in time-and dosedependent manners. In addition, rhGDF-5 treatment enhanced the expression of osteocalcin at both mRNA ( Fig. 2A and B ) and protein level ( Fig. 2C and D) in timeand dose-dependent manners. Furthermore, the immunofluorescence studies demonstrated that osteocalcin expression was predominantly located at the cytoplasm of the rhGDF-5-challenged cells, but not in the control cells (Fig. 2E ). More analysis of osteogenic differentiation by Alizarin red staining revealed that there was the presence of mineralized nodules in the rhGDF-5 group, but not in the control cultures (Fig. 3) .
rhGDF-5 activated the ERK1/2, p38 but not JNK in LFCs
To gain insight into the molecular mechanism underlying the osteogenic effects of rhGDF-5 on LFCs, we investigated the activity of MAPK in LFCs treated with rhGDF-5. As shown in Fig. 4A and B, rhGDF-5 treatment had not significant effect on the expression levels of ERK1/2, p38 and JNK, but induced the phosphorylation of ERK1/2 (Fig. 4A) and p38 (Fig. 4B ) in a time-dependent manner, while the phosphorylation of JNK (Fig. 4C) was not observed. The phosphorylated ERK1/2 and p38 MAPK were increased approximately 15-fold and 12-fold, respectively, in rhGDF-5 group compared with the control cells.
rhGDF-5-induced osteogenic differentiation of LFCs was mediated by ERK 1/2 and p38 MAPK
To further investigate whether the activation of ERK1/2 and p38 was linked to the osteogenic effect of rhGDF-5 in LFCs, we used specific inhibitors to block the phosphorylation of ERK1/2, or p38, respectively, and the markers of cell osteogenic differentiation were then measured. In these experiments, LFCs were stimulated with rhGDF-5 in the presence or absence of ERK 1/2 specific inhibitor U0126 or p38 specific inhibitor SB203580 at the concentration of 20 µM. As shown in Fig. 5 , ERK1/2 and p38 phosphorylation were completely inhibited by their specific inhibitors, respectively ( Fig. 5A  and B) . Moreover, U0126 and SB203580 significantly inhibited rhGDF-5-induced the increases of ALP activity and osteocalcin protein expression (Fig. 5C and D) . These results suggested that rhGDF-5-induced osteogenic differentiation of LFCs was dependent on the activation of ERK 1/2 and p38 MAPK.
Discussion
OLF is definitely a pathological lesion of ectopic ossification originating from the ligamentum flavum tissue. Histologic study revealed that the developmental mode of OLF was mainly endochondral ossification [1] . In vitro and in vivo studies have indicated that the pathogenesis of OLF was associated with osteogenic differentiation of the spinal ligament cells [30] [31] [32] . Increased recognition of the nature of OLF has highlighted the importance of determining the molecular mechanisms of osteogenic differentiation of LFCs. The present study demonstrated that rhGDF-5 induced osteogenic differentiation of LFCs through the activation of ERK1/2 and p38 MAPK. To the best of our knowledge, this is the first study to report the osteogenic effect of GDF-5 on LFCs.
An important finding of this study was that rhGDF-5 treatment induced osteogenic differentiation of cultured LFCs. An in vitro study has shown that BMP-2, an importance osteogenic growth factor, induced high ALP activity in normal LFCs from patients without OLF [32] . Previous studies have also reported that BMPs and BMP receptors expressed in ossified ligament tissue from OLF patients and BMP induced OLF in a mice model [8, 31] . We have recently demonstrated that the cultured LFCs from OLF patients manifest phenotypic characteristics of osteoblasts as revealed by expression of osteocalcin, a specific maker of osteoblasts [24] . Therefore, all these studies suggested that LFCs had a great potential to differentiate into osteogenic cells, and this could be the key events in the onset and development of OLF.
Several studies revealed that GDF-5 plays a pivotal role in a variety of musculoskeletal processes including endochondral ossification [33, 34] , joint formation [11, 35] , tendon and ligament maintenance and repair [36, 37] . In addition, GDF-5 has been demonstrated to play a role in osteogenesis and ectopic bone formation [12] [13] [14] [15] [16] [17] . Here, we found that rhGDF-5 induced osteogenic differentiation of LFCs as revealed by the increase of ALP activity, expression of osteocalcin and mineralized nodule formation. The present results supported the evidence that GDF-5 had the potential for osteogenic differentiation. A previous study has shown GDF-5 expressed in spindle-shaped cells and chondrocyte-like cells at ossified sites of the ligaments from OLF patients [20] . Taken together, these findings indicated that endogenous GDF-5 may regulate osteogenic differentiation of the spinal ligamant cells in an autocrine and/or paracrine manner. GDF-5 can bind to the type I receptor BMPR-IB and the type II receptors BMPRII and ActRII [38] . Through these BMP receptors, GDF-5 initiates intracellular signaling through the activation of downstream substrates, including MAPK signaling molecules. Here, we provided two lines of evidence supporting rhGDF5-induced activation of MAPK in LFCs. First, the presence of rhGDF-5 induced specifically the phosphorylation of ERK1/2 and p38, but had not effect on JNK. Second, the pretreatment of U0126, an ERK1/2 specific inhibitor, and SB203580, a p38 specific inhibitor, blocked rhGDF-5-induced the phosphorylation of ERK1/2 and p38, respectively. These findings suggested that rhGDF-5 induced activation of ERK1/2 and p38 MAPK in LFCs. Consistent with our result, previous studies have shown that GDF-5 induced the phosphorylation of ERK1/2 and p38 in ATDC5 cell line [39] and activated ERK1/2 in human umbilical vein smooth muscle cells [40] .
Evidence has accumulated to indicate that MAPK play an important role in the regulation of cell osteogenic differentiation [23, 41, 42] . Recent studies have demonstrated that the activation of MAPK signaling cascade contributes to osteogenic differentiation of cultured LFCs induced by mechanical stress and leptin, which were considered as the causes of OLF [25, 43] . However, whether the activation of ERK1/2 and p38 MAPK is involved in rhGDF-5 induced LFCs differentiation need to be further studied. In our study, the ERK1/2 inhibitor (U0126) or p38 inhibitor (SB203580) inhibited significantly rhGDF-5-induced increase in both ALP activity and osteocalcin expression. These results suggest that rhGDF-5-induced osteogenic differentiation of LFCs is mediated by the activated ERK 1/2 and p38 MAPK.
In conclusion, this study demonstrates that rhGDF-5 induces osteogenic differentiation of cultured LFCs through the activation of ERK1/2 and p38 MAPK. These findings give some new insight into the pathogenesis of OLF, and may set the basis for pharmacological intervention of OLF patients.
